Podcasts about Libre

                                     Honduras Election Chaos: Leftist Defeat and Geopolitical Implications — Evan Ellis — Ellis analyzes the chaotic Honduran presidential election wherein the ruling leftist Libre Party experienced electoral defeat after preliminary projections suggested victory. Ellis details the tight electoral race between centrist candidate Nasralla and Trump-endorsed candidate Asfura, warning that the electoral outcome will substantially impact U.S. counter-narcotics cooperation effectiveness and whether Honduras restores diplomatic recognition to Taiwan or maintains China relations. 1866

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big FDA recall around Freestyle Libre (see more below to find out if you're affected), Dexcom launches their 15.5 day sensor, Omnipod announces enhancements, Tandem tests a fully closed loop (with high fat, high carb meals) and lots more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. Our top story this week: XX Certain glucose monitors from Abbott Diabetes Care are providing users with incorrect glucose readings, an error that has been linked with the deaths of at least seven people and more than 700 serious injuries worldwide, according to an alert from the US Food and Drug Administration.   Incorrect glucose readings can lead to improper treatment. Abbott warned that about 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors are affected, but no other Libre products. Patients can visit FreeStyleCheck.com to see if their sensors are affected and to get a replacement for free.   The FDA has also published specific information about the affected products in its alert. The agency considers this to be a "potentially high-risk issue" and will continue to update its website as information becomes available.   "Patients should verify if their sensors are impacted and immediately discontinue use and dispose of the affected sensor(s)," the FDA said.   https://www.cnn.com/2025/12/02/health/abbott-diabetes-glucose-monitors https://www.freestylecheck.com/us-en/home.html XX Omnipod 5 is getting some enhancements.. and Omnipod 6 is announced. The FDA cleared updates including  a lower, 100 mg/dL target glucose option and what they call a more seamless automated experience. "This is the most significant algorithm advancement to our Omnipod 5 System since its launch in 2022," said Eric Benjamin, Insulet EVP and COO. Insulet said the new 100 mg/dL target glucose expands Omnipod 5's customization range. It now features six settings between 100 mg/dL and 150 mg/dL in 10 mg/dL increments. The company said this flexibility allows healthcare providers to tailor insulin delivery more precisely. It supports individuals seeking tighter glucose management or aiming to meet specific glucose goals. Omnipod 5's latest upgrades also help users stay in "Automated Mode" with fewer interruptions, even during prolonged high glucose events. Insulet plans to launch the updates to the algorithm in the first half of 2026. The company announced plans for an Omnipod 6 – without a lot of detail - at the company's Investor Day event in November. They also talked about a new, fully closed-loop pump for the type 2 diabetes population. https://www.drugdeliverybusiness.com/insulet-fda-clearance-omnipod-5-algorithm-enhancements/ XX Dexcom, the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System will launch in the United States on Dec. 1, making it the longest-lasting CGM system with 15.5 days of wear.   Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers on Dec. 1 with full retail launch in the coming weeks. Dexcom G7 15 Day will also be covered for Medicare beneficiaries.   Dexcom G7 15 Day's industry-leading wear-time will provide fewer sensor changes, less disruption and more time for people with diabetes to benefit from life-changing CGM technology.   New with Dexcom G7 15 Day:  Longest lasting CGM system with 15.5 days of wear. Best-in-class accuracy1 with an overall MARD of 8.0%. Easier glucose management with fewer monthly sensor changes and reduced monthly waste. This follows yesterday's announcement – the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults 18 and older with Type 2 diabetes using long-acting insulin. Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as directed by their healthcare provider. At launch, Dexcom G7 15 Day will connect with the iLet Bionic Pancreas and Omnipod® 5§§. We are working closely with Tandem and look forward to extending the launch to their customers shortly as they finalize integration. For specific information on pump compatibility and availability with the Dexcom G7 15 Day system, visit Dexcom.com/connectedpumps https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Continuous-Glucose-Monitoring-System-to-Launch-on-Dec--1-in-the-United-States/default.aspx   XX A small study of ten adults with type 1 diabetes tested Tandem's new fully closed-loop "Freedom" insulin system — and the participants put it through a real-world stress test. For 72 hours in a hotel setting, they ate heavy carb-and-fat meals, skipped all meal announcements, and didn't give any mealtime insulin boluses. The system handled almost everything automatically. Researchers said the device stayed in closed-loop mode 97% of the time and there were no incidents of diabetic ketoacidosis or severe hypoglycemia reported. While using the Freedom system, participants spent a median 61% of the day in the glucose target range — slightly higher than the 56% achieved with their usual pump at home. But the biggest improvement came overnight: time in range jumped to 96% with the closed-loop system compared to just under 70% during their home-pump week. With almost zero time spent below 70 mg/dL, researchers concluded that the fully automated Tandem system was both safe and effective even with unannounced, high-impact meals — hinting at a future of diabetes management that demands less effort from users.   XX Novo Nordisk reported promising mid-stage results for its experimental drug amycretin (AM-ee-creht-in) in diabetes patients on Tuesday. Amycretin, targets both GLP-1 and amylin hormones. In this study, it helped patients with type 2 diabetes lose up to 14.5% of their body weight over 36 weeks with weekly injections, far outperforming a placebo. The oral version delivered weight loss of up to 10.1%. Rival Eli Lilly  is surging ahead with its own amylin-based drug, eloralintide, which is advancing to late-stage testing after helping patients shed as much as 20% of their weight in a mid-stage trial. https://www.cnbc.com/2025/11/25/novos-next-gen-obesity-drug-shows-positive-results-heads-to-late-stage-testing.html XX The U.S. Medicare health plan said on Tuesday that newly negotiated prices for 15 of its costliest drugs will save 36% on those medications compared with recent annual spending, or about $8.5 billion in net covered prescription costs. The prices go into effect in 2027, including a monthly price of $274 for Novo Nordisk's popular GLP-1 drug semaglutide, sold as Wegovy for weight loss and Ozempic for diabetes. medicare's recent net price for Ozempic, opens new tab was $428 a month, according to an analysis published in the Journal of Managed Care and Specialty Pharmacy. Medicare put the drug's list price, before confidential rebates and discounts, at $959 a month. Based on such nondiscounted list prices, Medicare said savings on the 15 drugs ranged from 38% to 85%. The annual price negotiations were established under President Joe Biden's signature Inflation Reduction Act (IRA) of 2022. Previously, Medicare was barred by law from negotiating with drugmakers. https://www.reuters.com/business/healthcare-pharmaceuticals/us-negotiated-medicare-prices-15-more-drugs-test-cost-savings-promise-2025-11-25/   XX LifeScan announced its Chapter 11 bankruptcy reorganization plan received U.S. Bankruptcy Court approval. LifeScan said it's positioned to emerge from its financial restructuring process by the end of the year. The CEO says, "This balance sheet restructuring provides a stronger foundation for LifeScan to support our base business, advance new growth strategies, and commence our journey to become one of the most comprehensive players in the glucose management space." https://www.drugdeliverybusiness.com/glucose-monitor-lifescan-emerge-from-bankruptcy/ XX An artificial intelligence (AI)-led Diabetes Prevention Program (DPP) was as effective as a traditional human-led program in achieving recommended goals for weight loss, A1c reduction, and physical activity, according to a randomized trial of adults with prediabetes and overweight or obesity. One example of a push notification: "Looks like you're at the grocery store, Rita! Want a quick list of high-fiber snacks or smart swaps to stay on track this week?" The app also provided location- and goal-based education, with gamification elements to promote engagement. Approximately one third of participants in both the AI and human-led groups achieved the primary outcome (31.7% and 31.9%, respectively). Results were consistent across sensitivity analyses and individual components of the composite endpoint. "As more AI-based programs emerge, head-to-head comparisons among different AI-DPPs will be informative. An AI-led approach will not suit everyone; some individuals benefit more from human interaction and accountability," said Mathioudakis, adding that future research should focus on best matching patients to the modalities they prefer. https://www.medscape.com/viewarticle/ai-directed-diabetes-prevention-program-effective-human-2025a1000xam XX A new study suggets metformin could help people with type 1, reducing the need for insulin.  The researchers were surprised to find that metformin did not improve insulin resistance or change blood sugar levels. This suggests that, unlike in type 2 diabetes, metformin doesn't combat insulin resistance in type 1 diabetes.   However, metformin did reduce the amount of insulin people needed to keep their blood sugar levels stable.   https://www.the-express.com/news/health/192157/diabetes-medicine-insulin-type-1 XX Beyond Type 1 launches #TheBeyondType campaign in India to combat type 1 diabetes stigma. Nick Jonas is one of the founders of Beyond Type 1, his wife, Priyanka Chopra Jonas is his partner in this new non profit. The initiative highlights inspiring individuals living with T1D and partners with local organisations to improve awareness, medical support, and community networks for affected families across the nation. India has more young people living with T1D than any other nation, yet understanding of the condition remains limited. Beyond Type 1 is partnering with grassroots organisations across high-need regions. These include HRIDAY in Delhi–NCR, Nityaasha Foundation in Pune, Gram Jyoti in Jharkhand, and SAMATVAM Trust in Bangalore—each group focusing on improving awareness, providing medical support and building stronger community networks for young people with T1D.

In this episode of POD256, Tyler and eco catch up on winter in Colorado, project trucks, and then dive deep into the latest in Bitcoin mining and freedom tech. We recap last week's conversation with Keonne Rodriguez of Samourai Wallet, the urgent push for signatures on the pardon petition, and practical ways to support; while clarifying privacy-friendly ways to sign. We also discuss GrapheneOS stepping back from France amid regulatory pressure, the broader trend of governments targeting toolmakers, and why freedom tech from Bitcoin mining to open hardware matters now more than ever.On the mining front, we showcase Hydra Pool, our open-source non-custodial pool software, now running in our lab and soon to be public for Telehash #3 and beyond. We walk through the Grafana dashboard, PPLNS accounting for up to 100 addresses per coinbase, and our goal to migrate community hash over for solo mining support. We also update on Ember One and Libre Board: open-source hashboard and controller hardware moving through v5 prototyping on our pick-and-place, aiming for developer kits before fully assembled plug‑and‑play units. We hit Bitmain's reported federal probe, solo block wins by small hashers, and the path to open hardware parity. We close with hasher shoutouts and a call to action: sign the Samourai petition and join Telehash to help fund open mining R&D.

Les auditeurs de la Libre antenne de Roland Perez de ce lundi 1er décembre 2025 :  SOPHIE : 22H32/23H22Un ami de Sophie lui fait vivre un enfer... LUDOVIC : 23H27/23H54Ludovic a perdu l'amour de sa vie FRANCK : 00H04/00h33Après 15 années d'amour, Franck a été mis à la porte. SYLVIE : 00h37/01h00Sur fond de succession, la famille de Sylvie se déchire.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Les auditeurs de la Libre antenne de Valérie Darmon du dimanche 30 novembre 2025 :  Fathia : 22h32 – 23h39Les relations amoureuses de Fathia laissent perplexe Philippe, qui, lui, a connu le grand amour. Thierry : 23h42 – 23h55Thierry raconte avoir retrouvé l'amour après le décès de sa femme. Thérèse : 00h05 – 00h37Thérèse ne sait pas comment dire à son ami qu'elle n'est pas disponible pour lui. Laurène : 00h42 – 01h00Victime de crises de panique, Laurène cherche à comprendre ce qui déclenche ces épisodes et comment les apaiser.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Santiago Ortega

Vous rêvez de vivre de votre activité en freelance tout en gardant du temps pour vos projets créatifs ? Dans cet épisode, vous allez adorer découvrir le parcours d'Ilhem Ayad, freelance en marketing, responsable du programme d'affiliation de Livementor… et apprentie actrice / stand-uppeuse.

Mon but dans cette émission est de faire découvrir des artistes que l'on dit « émergents » et des nouveaux albums. J'aime beaucoup aussi parler des collaborations entre les artistes (musiciens, auteur, choriste, réalisation etc). Bien évidemment, je ne néglige pas non plus les artistes établis et leur nouveau matériel. Je demeure principalement ancré dans l'actuel et majoritairement du côté de la francophonie. Suzanne Castonguay

Chaque jour, écoutez le Best-of de l'Afterfoot, sur RMC la radio du Sport !

Les clubs RFI fêtent leurs 30 ans. L'occasion de leur donner la parole ce vendredi dans une Libre antenne spéciale. Engagés dans 25 pays, ils nous présenteront leurs actions citoyennes en faveur de l'éducation, de l'environnement, des réfugiés. Ils nous parleront de leur mobilisation pour l'élimination des violences faites aux femmes ou encore leurs initiatives contre les infox.  

Pemex registra otra caída  Edomex impulsa campaña “Ponte Croqueta” para apoyar a animales rescatadosCierran la Cinémathèque française por plaga de chinchesMás información en nuestro podcast

Tres candidatos se disputan la Presidencia de Honduras este 30 de noviembre: Rixi Moncada, Salvador Nasralla y Tito Asfura. El politólogo hondureño Sergio Vélez nos ayuda para trazar las fortalezas y debilidades de los tres.   Por Carlos Herranz, desde Tegucigalpa La candidata oficialista del Partido Libre, la abogada Rixi Moncada, es la opción de una izquierda que llegó para poner fin al bipartidismo, pero que ha caído en muchas de las inercias de sus antecesores. Moncada, un carácter fuerte que podría jugar en su contra “Rixi Moncada es una persona que tiene el conocimiento claro de la gestión de gobierno que han estado realizando. Tiene un respaldo muy fuerte por parte de la militancia de Libre. Se le ha reconocido como la gran lideresa. Es de un carácter fuerte, tiene un temple que ha llevado a saber de que es una persona de armas tomar”, explica a RFI el politólogo hondureño Sergio Vélez. Sin embargo, aunque esto puede ser “una gran fortaleza”, también podría ser “su propia debilidad, porque ante otros esa dureza que ha expresado de manera externa ha generado poca empatía con otros sectores que pueden ser de interés dentro del electorado”. Nasralla, el showman que no convence a todos Por parte del Partido Liberal está Salvador Nasralla, un showman populista que ya pactó con la izquierda hasta que su coalición explotó, y al que se suele culpar de dar bandazos ideológicos para llegar al poder. “Salvador Nasralla, bajo el criterio propio, es una persona muy carismática. Viene de un aspecto del showman, donde él sabe cómo manipular audiencias, cómo decir lo que la gente quiere escuchar”, subraya Vélez. Pero, estima el politólogo, “también se vuelve en un aspecto una desventaja. ¿Por qué? Porque para muchos, es un criterio bastante superficial, más por el hecho de que hoy puede decirte algo y mañana cambia toda la temática y cambia toda la idea, no termina de cuajar con la idea de estadista que se está esperando de alguien que va a tener la primera silla del país”. Asfura, el heredero Tito Asfura, el empresario conservador al que Donald Trump ha dado su bendición, remodeló muchas infraestructuras como alcalde de Tegucigalpa, un activo que se contrapone al lastre de haber heredado las riendas del Partido Nacional, el mismo del expresidente condenado por narcotráfico, Juan Orlando Hernández. “Asfura es una persona más reservada. Le gusta trabajar más que estar en cámara. Puede que por eso se le acuse que sea un poco parco. Vamos a la circunstancia de que él entra bajo un criterio y una sombra que no es de él. Y fue lo que pasó con Juan Orlando Hernández, ex presidente del país”, recalca Sergio Vélez. Las acusaciones de fraude reavivan los fantasmas de la noche electoral de 2017, cuando tras un apagón de energía, los nuevos resultados encumbraron al presidente Juan Orlando Hernández hacia una reelección, acompañado de un estallido social en el que murieron al menos 23 personas, según la ONU.

Les auditeurs de la Libre antenne de Valérie Darmon de ce jeudi 27 novembre 2025 :  Flora : 22h31 à 22h52Déçue par les sites de rencontre, Flora cherche encore le véritable amour. Caroline : 22h58 à 23h51En recueillant des animaux, Caroline panse ses blessures et retrouve un équilibre. Dorothée : 23h53 à 00h20En couple depuis 13 ans, Dorothée partage ses secrets pour faire durer l'amour. Gérard : 00h24 à 00h35Gérard rappelle l'importance de transmettre l'histoire familiale aux enfants. Françoise : 00h38 à 00h55Françoise dénonce les comportements irrespectueux de certains hommes envers les femmes.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Tres candidatos se disputan la Presidencia de Honduras este 30 de noviembre: Rixi Moncada, Salvador Nasralla y Tito Asfura. El politólogo hondureño Sergio Vélez nos ayuda para trazar las fortalezas y debilidades de los tres.   Por Carlos Herranz, desde Tegucigalpa La candidata oficialista del Partido Libre, la abogada Rixi Moncada, es la opción de una izquierda que llegó para poner fin al bipartidismo, pero que ha caído en muchas de las inercias de sus antecesores. Moncada, un carácter fuerte que podría jugar en su contra “Rixi Moncada es una persona que tiene el conocimiento claro de la gestión de gobierno que han estado realizando. Tiene un respaldo muy fuerte por parte de la militancia de Libre. Se le ha reconocido como la gran lideresa. Es de un carácter fuerte, tiene un temple que ha llevado a saber de que es una persona de armas tomar”, explica a RFI el politólogo hondureño Sergio Vélez. Sin embargo, aunque esto puede ser “una gran fortaleza”, también podría ser “su propia debilidad, porque ante otros esa dureza que ha expresado de manera externa ha generado poca empatía con otros sectores que pueden ser de interés dentro del electorado”. Nasralla, el showman que no convence a todos Por parte del Partido Liberal está Salvador Nasralla, un showman populista que ya pactó con la izquierda hasta que su coalición explotó, y al que se suele culpar de dar bandazos ideológicos para llegar al poder. “Salvador Nasralla, bajo el criterio propio, es una persona muy carismática. Viene de un aspecto del showman, donde él sabe cómo manipular audiencias, cómo decir lo que la gente quiere escuchar”, subraya Vélez. Pero, estima el politólogo, “también se vuelve en un aspecto una desventaja. ¿Por qué? Porque para muchos, es un criterio bastante superficial, más por el hecho de que hoy puede decirte algo y mañana cambia toda la temática y cambia toda la idea, no termina de cuajar con la idea de estadista que se está esperando de alguien que va a tener la primera silla del país”. Asfura, el heredero Tito Asfura, el empresario conservador al que Donald Trump ha dado su bendición, remodeló muchas infraestructuras como alcalde de Tegucigalpa, un activo que se contrapone al lastre de haber heredado las riendas del Partido Nacional, el mismo del expresidente condenado por narcotráfico, Juan Orlando Hernández. “Asfura es una persona más reservada. Le gusta trabajar más que estar en cámara. Puede que por eso se le acuse que sea un poco parco. Vamos a la circunstancia de que él entra bajo un criterio y una sombra que no es de él. Y fue lo que pasó con Juan Orlando Hernández, ex presidente del país”, recalca Sergio Vélez. Las acusaciones de fraude reavivan los fantasmas de la noche electoral de 2017, cuando tras un apagón de energía, los nuevos resultados encumbraron al presidente Juan Orlando Hernández hacia una reelección, acompañado de un estallido social en el que murieron al menos 23 personas, según la ONU.

Les auditeurs de la Libre antenne de Roland Perez du mercredi 26 novembre 2025 :  PHILIPPE : 22h20/22h59Par amour pour son fils, Philippe fait de leur tragédie un engagement. LAETITIA : 23h05/23h48La fratrie de Laetitia se déchire autour de leur mère. RACHEL : 23h53/00h39En soutenant son fils, Rachel s'est faite arnaquer. LINDA : 00h43/01h00En donnant naissance à sa dernière fille, les viols de Linda lui sont revenus en mémoire.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Chef d'entreprise? Téléchargez ce Guide Offert : https://max-piccinini.com « Les 7 moyens pour booster votre C.A. de 100 à 200 % ».Si vous êtes nouveau sur ma chaîne, je m'appelle Max Piccinini. J'ai développé un patrimoine de plus de 50 millions d'euros en partant de zéro (avec un Bac + 1 et une semaine de travail :-)).Je suis l'auteur best-seller du livre « Réussite Maximum ». Mon entreprise est leader sur le marché de l'accompagnement pour chefs d'entreprise.Nous réalisons près de 15 millions d'euros de chiffre d'affaires annuel, et notre passion est d'aider les chefs d'entreprise comme vous à « scaler » leur entreprise, booster leur rentabilité, décupler leur valorisation, et se libérer de l'opérationnel.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Después de mucho tiempo volvemos a hacer conversación libre sobre todo y nada para hablar sobre el sueño de Shakti poseída, la nueva temporada de Stranger Things, Thanksgiving y mucho más.

Esta noche, la escritora Belén Gopegui nos hace pensar en cómo está estructurada la sociedad y el papel que jugamos en ella. Hemos elegido para asomarnos a su trayectoria su libro 'El padre de Blancanieves'. Hablamos con Raquel Alarcón, directora de 'Historia de una maestra', la obra de teatro que rinde homenaje a Josefina Aldecoa, fundadora, en plena dictadura, del Colegio Estilo, inspirado en la Institución Libre de Enseñanza, en su madre y otros maestros republicanos que priorizaron en clase la cultura y la libertad individual o religiosa. Como cada martes, Alejandro Pelayo se asoma al piano de la ser. 

Les auditeurs de la Libre antenne de Roland Perez de ce lundi 25 novembre 2025 :  JEAN MARC : 22h34/23h24Victime de la Dépakine, Jean Marc alerte les futurs pères des dangers de ce médicament. MYRTILLE : 23h30/00h00Retraitée précaire, Myrtille a honte de ne pas pouvoir gâter ses enfants et petits-enfants.  ALAIN : 00h08/00h40Alain raconte son vécu en Guyane. MARIE LOUISE : 00h44/01h00La guerre en Ukraine révolte Marie LouiseHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

En entrevista con Pamela Cerdeira, para MVS Noticias, Mariana Campos, directora general de México Evalúa, explicó todo sobre la iniciativa 10 rutas para un México libre de pobreza.See omnystudio.com/listener for privacy information.

Les auditeurs de la Libre antenne de Roland Perez de ce lundi 24 novembre 2025 :  JEAN LOUIS : 22H33/23H28Devenu aveugle par accident; le handicap de Jean Louis a décuplé son désir de vivre.https://www.editions-harmattan.fr/catalogue/livre/aveugle-mode-d-emploi/79990?srsltid=AfmBOooV9Ew8NStQoXfTUXH-BBL3SMAZ7B_HSGglx-1pRmTW5MgDZEbK JEANNOT : 23H34/23H55Jeannot est très inquiet pour sa fille qui pourrait perdre la garde de son enfant. ALEX & CO : 00H05/00H27La résidence Parisienne pour aveugles d'Alexandre va être déplacée à Nanterre par l'association Valentin Haüy contre leur gréshttps://c.org/Lf42G5Fgt9 ELISABETH : 00H33/01H00Poète allergique à la technologie, Babeth a besoin d'aide pour écrire son 3è recueil.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Pourquoi semble-il évident que l'être humain soit la seule créature capable de choisir ? Qu'en est-il réellement ? Un ange ou un animal peuvent-il être sanctionnés ? Ont-ils, par conséquent, un libre arbitre ? Réponse à travers des propos du propos du Midrach Rabba et du Ram'hal.

durée : 00:25:09 - Francesco Tristano, pianiste (1/5) - par : Judith Chaine - Francesco Tristano réinvente le classique à sa manière, flirtant avec jazz et électro. Libre et intrépide, sa démarche bouscule les codes tout en restant fidèle à la tradition. Retour en 5 épisodes sur le parcours de cet iconoclaste pianiste . - réalisé par : Adrien Roch Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Francino reflexiona sobre la condena al fiscal general y el juicio a Jordi Pujol y como estos reabren el debate sobre la credibilidad del sistema.

Este, como todos los lunes, escuchamos y reaccionamos a las cancion es que nos sugieren o recomiendan durante la semana. No se lo pierdan.Canciones mencionadas en orden :Rodrigo Cano y Los Canes - Ya no quiero ser asíCuervos in Venus - Enemigo del VaivenDelatores - Entrego al MarLuz Pinos - Un campitoDrica - La despedidaBri!!0 - rockstarSuperdedores - T VasGran Radio Riviera - X tiJavier Panigua - Vals No1Abi Difabio - LlaveritoKany Garcia - Tierra LibrePlena Libre, Elvis Crespo - CarnavalMyles Lloyd - Are U in MTLStill Blank - Dead & GoneBranson Cyrus, Noah Cyrus - As long as you'll staySíguenos en:                                                                                                                                                                                                                                                                                                                                                                                                                       Instagram: @mixtape_lado_aSpotify: Mixtape: Lado A                                                   Youtube: Mixtape Lado AApple Podcast: Mixtape Lado A

Les auditeurs de la Libre antenne de Valérie Darmon de ce dimanche 23 novembre 2025 :  Camille : 22h32 – 23h00Diagnostiqué schizophrène et bipolaire, Camille est aujourd'hui stabilisée. Laurette : 23h04 – 23h35La petite-fille de Laurette est en perdition. Marc : 23h40 – 00h18Après une longue errance amoureuse, Marc a trouvé une compagne. Dominique : 00h19 – 00h31  Dominique souhaite mettre en lumière le réseau fluvial français. Jo : 00h36 – 00h56Psycho-coiffeur, Jo présente son métier.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Les auditeurs de la Libre antenne de Roland Perez du jeudi 20 novembre 2025 : NATHALIE : 22h33/23h23Après le vol de son chien, Nathalie a créé WAF, une association pour changer les loiswww.association-waf.com BRIGITTE : 23h28/00h00Brigitte est en conflit avec le déménageur désastreux avec qui elle a eu à faire.  BOLCHOÏ : 00h05/01h00L'ex pervers narcissique de Bolchoï a la garde de leurs enfants.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Santiago Ortega

PREVIEW Mary Anastasia O'Grady of the Wall Street Journal editorial page discusses the upcoming Honduran election, noting the risk of it being stolen by the ruling Libre party. Current President Castro, associated with a former drug-trafficking president, won on promises of cleaning up corruption, but this has failed. Despite trailing, the party is suspected of taking actions to retain power. Guest: Mary Anastasia O'Grady.

durée : 02:01:38 - Les Nuits de France Culture - par : Albane Penaranda, Mathias Le Gargasson, Antoine Dhulster - Par Antoine Garapon et Claude Weill - Avec Claude Jorda (juge à la Cour Pénale Internationale), Rony Brauman, (ancien président de Médecins sans frontières, professeur à Sciences Po), Henry Rousso (historien, directeur de l'Institut d'histoire du temps présent), Karl Hofmann (ministre conseiller à l'ambassade des Etats-Unis à Paris), Sidiki Kaba (avocat sénégalais, président du bureau international de la FIDH) et Anta Guisse (avocate franco-sénégalaise) - Avec en archives, la voix de Slobodan Milosevic lors de son procès - Réalisation Marie-France Thivot - réalisation : Rafik Zénine, Vincent Abouchar, Emily Vallat

Please note this episode of Type 1 on 1 contains honest discussion of severe depression at around 1'08", including suicidal thoughts. No matter how long you've been living with or close to type 1 diabetes, it remains an incredibly complex condition to understand. And while there's a wealth of information out there to dig into, knowing what to pay attention to can be just as daunting. John Pemberton is a diabetes technology consultant, children's dietician, researcher and has been living with type 1 diabetes himself for around 20 years. So if you're looking for research-backed information about the right insulin pump, want to know why 20 minutes of walking is the magic key to a stubborn high glucose reading, or you just need to start with the basics without getting overwhelmed, his diabetes education platform The Glucose Never Lies could be the answer. It was created after his young son Jude tested positive for diabetes antibodies, and when it comes to distilling complicated diabetes information and making it make sense, John is a master of the craft.In this episode we cover an incredible amount - from the professional, including his work with newly diagnosed families, the latest in diabetes research and his love of continuous glucose monitoring, to the deeply personal, including how years of undiagnosed ADHD led to severe depression and suicidal thoughts. After getting the right treatment in July 2025, John has found renewed purpose in taking The Glucose Never Lies to the next level.CONNECT WITH JOHNThe Glucose Never Lies Website The Glucose Never Lies Podcast on Spotify Diabetes Specialist Nurse Forum CGM comparison chart.DISCLAIMER Nothing you hear on Type 1 on 1 should be taken as medical advice. Please consult your healthcare team before making any changes to your diabetes or health management.JOIN THE TYPE 1 ON 1 COMMUNITY:Come and say hi @studiotype1on1 on Instagram.Visit the Type 1 on 1 website.Subscribe to the Type 1 on 1 newsletter.SPONSOR MESSAGEThis episode of Type 1 on 1 is sponsored by Dexcom. Using Dexcom CGM has given me so much confidence to make informed diabetes treatment decisions in the moment.You can choose to wear it on your arm or your abdomen, and all Dexcom CGMs have the share and follow feature even when connected to an insulin pump, so family and friends can see your glucose levels and get alerts, giving that extra bit of support when needed.Head to Dexcom.com to request a free Dexcom ONE+ sample.Always read the user manual for important product aspects and limitations. Talk to your doctor for diabetes management terms and conditions and terms of use. 

Santiago Ortega

Cliquez ici pour accéder gratuitement aux articles lus de Mediapart : https://m.audiomeans.fr/s/P-UmoTbNLs D'Éric Ciotti à Sarah Knafo, en passant par le Rassemblement national, l'extrême droite multiplie les propositions ultrafavorables à un écosystème libertarien de plus en plus bruyant, pourtant peu enclin à participer au jeu politique traditionnel. Un article d'Alexandre Berteau et Youmni Kezzouf, publié sur Mediapart le 19 novembre 2025, lu par Jeremy Zylberberg. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dans cette émission, Matthieu Lavagna s'appuie sur la réponse qu'il a faite à Michel Onfray, pour nous montrer les preuves historiques de l'existence de Jésus. Son ouvrage : Libre réponse à Michel Onfray : Non le Christ n'est pas un mythe aux éditions Artège

Dios tiene poder para darnos la libertad.

durée : 00:03:23 - Le billet de Sophia Aram - par : Sophia Aram - Quel bonheur, un an quasiment jour pour jour après son arrestation, l'écrivain Boualem Sansal est enfin libre de vivre, de parler, d'écrire, de publier : il est libre de faire son boulot d'écrivain. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

L'artiste malienne Rokia Traoré publie aux éditions J.-C. Lattès Je suis née libre. Disponible depuis le 29 octobre 2025, le livre interroge sur les rapports entre l'Europe et l'Afrique et sur les droits des femmes entre autres. Et la journaliste, mais aussi chanteuse Fanny Marsot présente Pani zétwal, chanson disponible depuis le 17 octobre et en collaboration avec le pianiste de jazz Jimmy Felvia. Pour visionner les clips, cliquez sur les titres des chansons :  Rokia Traoré - Tuit tuit Rokia Traoré - Nè so Fanny Marsot x Jimmy Felvia - Pa ni zetwal  Rokia Traoré - Tu voles  Rokia Traoré - Obikè Retrouvez la playlist officielle de RFI Musique.

L'artiste malienne Rokia Traoré publie aux éditions J.-C. Lattès Je suis née libre. Disponible depuis le 29 octobre 2025, le livre interroge sur les rapports entre l'Europe et l'Afrique et sur les droits des femmes entre autres. Et la journaliste, mais aussi chanteuse Fanny Marsot présente Pani zétwal, chanson disponible depuis le 17 octobre et en collaboration avec le pianiste de jazz Jimmy Felvia. Pour visionner les clips, cliquez sur les titres des chansons :  Rokia Traoré - Tuit tuit Rokia Traoré - Nè so Fanny Marsot x Jimmy Felvia - Pa ni zetwal  Rokia Traoré - Tu voles  Rokia Traoré - Obikè Retrouvez la playlist officielle de RFI Musique.

Stephan Livera and Kevin Cai dive into the Bitcoin spam debate, breaking down the different camps in the community, the line between consensus and policy, and how transaction filters, dust limits, and Libre Relay affect the network. They explore mining economics, fee dynamics, and the subjective nature of what people call spam.Kevin also discusses UTXO consolidation, decentralization, and how BRC-20 activity impacts the fee market. He explains the cultural differences behind spam opinions and the broader implications for Bitcoin's ecosystem.The conversation covers the challenges of Bitcoin development, including concerns around temporary fixes like RDTS, and why programmability matters for Bitcoin's future utility.Takeaways:

Hoy nos visita McEnroe para presentarnos su nuevo trabajo, La vida Libre. También viajamos a Berlín con nuestra corresponsal para escuchar dos piezas inéditas de Johann Sebastian Bach. También entrevistamos al Premio Ojo Crítico de Artes Plásticas 2019, David Bestué, que acaba de inaugurar un proyecto en la Plaza de España de Bruselas. Repasamos lo mejor de las artes escénicas con Marta García-Miranda y nos introducimos en la obra de Kiyoshi Kurosawa con Vicente Monroy.Escuchar audio

Meditaciones preparadas (aunque no exclusivamente) para hacer un retiro espiritual y mejorar en su vida cristiana, de oración y de trato con Dios. A cargo del Padre Ricardo Sada Fernández de México.

115 muertes al día por alcohol en México  Sheinbaum anuncia obras en carretera a Palizada, Campeche  Más información en nuestro Podcast

Nestor Duprey y Eduardo Lalo conversan en la Casa Soberanista durante el encuentro de palabralibristas efectuado el jueves 13 de noviembre de 2025.Conducido por Néstor Duprey Salgado y Eduardo Lalo.Síguenos en las redes:Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PalabraLibrePR⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Palabra Libre PR⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Página web: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Palabra Libre – Más allá del bipartidismo (palabralibrepr.com)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 

         Honduras is holding a high-stakes, single-round election where the outcome could determine if the country returns to alignment with Taiwan or shifts to China. Election observers noted improper pressure and concerns about meddling by the ruling Libre Party. Separately, Argentina's economy under Milei is strengthening, backed by a significant US currency swap and political support. Guest: Evan Ellis. 3/4

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922.   WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups.   Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that  kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, suggesting that a mother's condition during pregnancy can shape her child's immune response in a protective way. Scientists identified more than 500 areas of DNA where these changes occurred, many in regions that control how the body's immune system works. Most of the changes appeared to calm down the kind of overactive immune response that leads to type 1 diabetes. Researchers even created a "methylation score" to help measure this protective effect. They say the next step is to confirm these results in more diverse groups and figure out exactly how these DNA changes help prevent early diabetes. https://www.news-medical.net/news/20251110/Maternal-type-1-diabetes-may-protect-children-from-developing-the-disease.aspx XX A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape future strategies to prevent cardiovascular disease early in life.     Children of women with type 1 diabetes are known to be at increased risk of developing cardiovascular diseases. This new study, published in Cell Reports Medicine, is the first to show that the risk is linked to early dysfunction in blood vessel cells in sons, even before any metabolic issues arise. The team is now investigating the long-term effects of maternal diabetes, with a particular focus on why sons seem to be affected earlier than daughters. https://medicalxpress.com/news/2025-11-sons-mothers-diabetes-early-vascular.html XX A new study presented at Kidney Week 2025 has shown that the drug finn-uh-near-own  a nonsteroidal mineralocorticoid-receptor antagonist, significantly reduced albuminuria—a key marker of kidney damage—in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This is the first major breakthrough for this population in more than 30 years. Researchers found that patients taking finerenone saw a 25% average reduction in albuminuria compared to placebo, an improvement that suggests a lower long-term risk for dialysis or kidney transplant. The phase 3 FINE-ONE trial involved 242 adults with T1D and CKD, and results showed benefits as early as three months. The drug was generally well tolerated, with side effects similar to those seen in patients with type 2 diabetes, though mild hyperkalemia (high potassium levels) was slightly more common. Experts say the findings could change the way doctors treat kidney complications in type 1 diabetes, an area that hasn't seen new therapies since the early 1990s. Currently, treatment options rely on blood pressure and blood sugar management, along with renin-angiotensin system (RAS) inhibitors. Finerenone, which is already approved for type 2 diabetes-related CKD, targets overactivation of a receptor that drives kidney damage. Based on these results, Bayer plans to seek FDA approval in 2026 for use in people with T1D and CKD. Researchers and clinicians alike are calling the study "groundbreaking," noting that it opens the door to future research on how finerenone might not just slow kidney decline—but possibly prevent it altogether. https://www.medscape.com/viewarticle/finerenone-offers-hope-kidney-disease-type-1-diabetes-2025a1000uzi?form=login   XX This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software.   Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population.   We had a great interview with Tandem on our previous episode, but as I said at the time, it was coming before their earnings call. So here's an update: The company plans to submit the tubeless mobi to the fda before the end of this year.. possible approval and shipping date is hoped for by middle of 2026. Trials for their fully closed loop next-generation algorithm which we tlkaed abou ton the show should be launched in 2026 The Sigi patch pump will be developed and launched as a next-generation version of the Mobi Great job by Dr. David ? Ahn – he posted on IG after getting a message from tandem CEO John Sheridan? 1. First, the Tandem X3 *is* still absolutely in development, contrary to my speculation In yesterday's video. As many of you appropriately pointed out, there is definitely a market for a 300 unit pump, a pump with a screen, and a pump that does not require smartphone control. So from our brief chat, the sense I got that is that the X3 would be more of a refresh of the X2 with newer components, such as a USB-C connector and better memory, rather than a total redesign from the ground up. In terms of timing, all I could get was that it was "not too far distant in the future," which could mean anything I guess, but at least it's still on the way! 2. Next up, he also reassured me that they are working closely with Dexcom to support the G7 15 Day sensor within the next few months. I suspected as much, but it's always good to hear confirmation. 3. Lastly, he did confirm that Tandem is far along in developing a Caregiver/Follow app to allow the remote viewing of glucose and insulin data from a Tandem pump. He explained that it will be based on Sugarmate, the popular diabetes data dashboard app that Tandem acquired back in Jun 2020. While I don't know if every feature will make it into the Tandem caregiver app, Sugarmate is well-liked for its highly customizable dashboard and highly configurable alerts. Sugarmate even has the option to send a text message or phone call for urgent lows. Regardless, a true follow/Caregiver app will be welcomed with open arms by all caregivers and Tandem users who use Libre 3 Plus. https://time.com/7318020/worlds-top-healthtech-companies-2025/ XX Senseonics submits Eversense 365 – their year long implantable CGM for a CE mark, European Approval and expect to launch there soon. Eversense will be integrated with the sequel twist pump – again I'm hearing soon but no timeline. Intersting to note that one year inseration was approved in the US just about a year ago, so the first patients will be having their CGMs changed out – for the first time – pretty soon. https://www.drugdeliverybusiness.com/senseonics-q2-2025-sales-beat-ce-mark/ XX A confusing study out of Rutgers - these researcher say  metformin reduces some of the key benefits normally gained from regular physical activity. These include improvements in blood vessel health, physical fitness, and the body's ability to regulate blood sugar. Since 2006, doctors have typically encouraged patients with elevated blood sugar levels to combine metformin with exercise, expecting that the two proven treatments would produce stronger results together. However, the new research suggests this may not be the case. In this study, Exercise alone improved vascular insulin sensitivity, meaning blood vessels responded better to insulin and allowed more blood flow to muscles. This matters because insulin's ability to open blood vessels helps shuttle glucose out of the bloodstream and into tissues, lowering blood sugar after meals. But when metformin was added, the improvements shrank. The drug also diminished gains in aerobic fitness and reduced the positive effects on inflammation and fasting glucose. The findings don't mean people should stop taking metformin or exercising, Malin said. Instead, it raises urgent questions for doctors about how the two treatments can be combined and the need for close monitoring. Malin hopes future research will uncover strategies that preserve the benefits of both. https://scitechdaily.com/popular-diabetes-drug-metformin-may-cancel-out-exercise-benefits-study-warns/ XX XX https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/   XX Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or notifications related to estimated glucose values, according to a Food and Drug Administration database entry posted Oct. 30. The glucose sensor and the app are still available, but Dexcom required users to update the app to a new version. Dexcom began the recall on Aug. 28. The FDA designated the event as a Class 1 recall, the most serious kind. Dexcom sent a notification to customers in September about the software bug, which applies to version 1.15 of the G6 Android app. To use the app, customers must update it to a new version, according to the entry. https://www.medtechdive.com/news/dexcom-recall-g6-cgm-app/804630/ XX https://www.medscape.com/viewarticle/automated-insulin-delivery-boosts-glycemic-control-youth-2025a1000ub3 XX Tidepool partners with smart ring maker OURA.. press release says: to support a groundbreaking dataset intended to be broadly available for diabetes research, with participation limited to individuals who opt in through Tidepool.         Tidepool will pair biometric data from Oura Ring – sleep, activity, heart rate, temperature trends, and menstrual cycles – with diabetes device data, including continuous glucose monitors (CGMs) and insulin pumps. The result will provide researchers with an unprecedented dataset to accelerate the development of new clinical guidelines, next-generation diabetes technology, and personalized care models.   Recruitment is expected to launch in early 2026 through an IRB-approved study. By opting in to this study, participants consent to sharing their data with Tidepool's Big Data Donation Project, where data is de-identified and, with participant consent, shared with academics, researchers, and industry innovators to accelerate diabetes research. https://aijourn.com/tidepool-collaborates-with-oura-to-advance-inclusive-diabetes-research-through-wearables/ XX Eli Lilly launches two new clinical trials for baricitinib. These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Baricitinib has the potential to extend the "honeymoon period" of T1D, meaning that it could preserve remaining insulin-producing beta cells earlier in disease progression. More beta cells mean better blood sugar management—and potentially reduced long-term complications. JAK inhibitors, including baricitinib, are already FDA-approved for other autoimmune diseases, such as rheumatoid arthritis, alopecia, and more. JAK signaling pathways are associated with overactive immune responses, so blocking this pathway may turn down the immune response. The phase 2 Breakthrough T1D-funded BANDIT study was key in showing that this drug is safe and effective in T1D. Importantly, baricitinib is a once-daily oral pill—meaning its use is simple and easy.   https://www.breakthrought1d.org/news-and-updates/two-new-trials-baricitinib-to-delay-t1d/ XX   Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger changes in how workplaces approach the condition. Lots going on for Diabetes Awareness month.. some notables.. Insulet's "The Day Diabetes Showed up to Work" campaign. based on a survey of almost 10,000 people 79% of people with diabetes have faced bias or misunderstanding at work,.   Almost 90% of people with diabetes surveyed reported experiencing barriers at work due to their condition, and more than 40% of people with diabetes and caregivers said they have workplace-related anxiety tied to the metabolic disease. Around one-quarter of respondents reported fears that diabetes could limit opportunities or lead to workplace discrimination and judgment, and a similar proportion of people said they conceal their condition. https://www.fiercepharma.com/marketing/widespread-workplace-challenges-people-diabetes-spark-insulet-campaign XX New directive issued by the Trump administration could mean people seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity.   The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem applicants ineligible to enter the U.S. for several new reasons, including age or the likelihood they might rely on public benefits.   The guidance says that such people could become a "public charge" — a potential drain on U.S. resources — because of their health issues or age.   The cable's language appears at odds with the Foreign Affairs Manual, the State Department's own handbook, which says that visa officers cannot reject an application based on "what if" scenarios, Wheeler said.   The guidance directs visa officers to develop "their own thoughts about what could lead to some sort of medical emergency or sort of medical costs in the future," he said. "That's troubling because they're not medically trained, they have no experience in this area, and they shouldn't be making projections based on their own personal knowledge or bias."   Immigrants already undergo a medical exam by a physician who's been approved by a U.S. embassy. https://www.npr.org/2025/11/12/nx-s1-5606348/immigrants-visas-health-conditions-trump-guidance XX SAN DIEGO---Nov. 14, 2025—DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology. "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others." This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage. Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of. To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo*Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day. Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes. "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique an XX On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred E. Mann Charities and The Diabetes Link, announced the launch of the Centennial Al Mann Scholarship. The new program will distribute $100,000 in scholarship funds to support at least 10 young adult students living with diabetes as they pursue higher education in life sciences.   Launched in Diabetes Awareness Month, the scholarship program honors Alfred E. Mann's enduring legacy of innovation, philanthropy, and his lifelong commitment to improving the quality of human life through medical advancement. Deeply passionate about giving back, Mr. Mann believed that his success should continue to serve humanity long after his passing, a belief that lives on through this initiative.   Each scholarship recipient will be awarded up to $10,000, distributed in annual installments of $2,500 throughout the course of their studies. Depending on the length of their degree program, recipients may receive between two and four installments (up to the full $10,000 per student). The first awards will be made for the 2026 academic year.   "Al Mann dedicated his life to helping people with serious medical conditions live longer, healthier lives. This scholarship is a reflection of that spirit," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "By supporting students living with diabetes who are pursuing careers in the life sciences and adjacent fields, we're honoring Al's legacy and investing in the future of innovation and care. This program is about giving back to the community we serve and empowering the next generation to carry forward Al's mission of making a meaningful difference in people's lives."   Alfred E. Mann Charities and MannKind will partner with The Diabetes Link to launch the program to serve young adults (aged 18-22) living with either type 1 or type 2 diabetes with their higher education goals. Those eligible will include incoming freshmen and current students pursuing 2- or 4-year degrees. The application window will open in early 2026, and for those interested in receiving notifications, an early interest form is available. More information about the scholarship will be shared on thediabeteslink.org.   "We're honored to partner with MannKind to expand access to higher education for young adults with diabetes," said Manuel Hernández, Chief Executive Officer of The Diabetes Link. "At a time when the cost of college continues to rise, this scholarship helps ease the financial burden and carries forward the spirit of Al Mann, whose vision and legacy continue to inspire us."   Mr. Mann was MannKind's Chairman of the Board from 2001 until his passing in February 2016 and served as Chief Executive Officer from November 2003 until January 2015. Driven by a desire to improve lives and fill unmet medical needs, for more than six decades he founded 17 companies and developed breakthrough medical devices, including insulin pumps, cochlear implants, cardiac pacemakers and retinal prostheses. In 1997, Mr. Mann saw the potential of a dry powder insulin formulation to change the way diabetes is treated and invested nearly $1 billion to help bring Afrezza® (insulin human) Inhalation Powder to market.   About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.   With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.   Learn more at mannkindcorp.com.   About Alfred E. Mann Charities, Inc. Alfred E. Mann Charities, Inc. became active in 2016, following the passing of the organization's benefactor, Alfred E. Mann. Throughout his life, Al was passionate about philanthropy and was dedicated to prolonging and improving the quality of human lives through innovation in the fields of healthcare and the use of medical devices. It was important to Al that his success and assets continue to better human lives even after his own passing.   Alfred E. Mann Charities, Inc. (formerly known as Alfred E. Mann Family Foundation) has similarly placed its primary focus on healthcare and medical innovation, as our organization believes this is where we can have the greatest impact on humanity and human health throughout the world. Alfred E. Mann Charities, Inc. is also dedicated to promoting arts, culture, education, and community development across Los Angeles and throughout the world in order to best serve people and this planet.   Learn more at aemanncharities.org.   About The Diabetes Link The Diabetes Link is the only national nonprofit organization dedicated to empowering young adults living with diabetes. Founded by and for young adults, The Link serves this community through peer support, leadership opportunities, and practical, evidence-based resources designed for real life. Its network of campus and community chapters, active online community, and robust Resource Hub help young adults navigate the transitions of early adulthood while managing diabetes. The organization envisions a future where every young adult living with diabetes has

Le Journal en français facile du mercredi 12 novembre 2025, 17 h 00 à Paris Retrouvez votre épisode avec la transcription synchronisée et des exercices pédagogiques pour progresser en français : http://rfi.my/CB7l.A

¿Hasta qué punto podemos mostrarnos tal como somos cuando el entorno parece no estar preparado para sostenernos? ¿Qué sucede cuando abrimos nuestro corazón y, en lugar de empatía, encontramos rechazo? En esta conversación, Hermógenes nos habla de su proceso tras atravesar un momento de dificultad, del estigma, del dolor... pero también de su resurgir como el ave fénix gracias al perdón, la generosidad y el amor propio.En este nuevo episodio, me siento profundamente agradecido y honrado de compartir con vosotros una conversación de profunda transformación que nos facilita Hermógenes. A lo largo de ella también reflexionamos juntos sobre el crecimiento postraumático, el valor del perdón, el poder del amor propio y la importancia de abrazar nuestras heridas como parte de nuestra evolución.

We've got an update from Tandem Diabetes. We're talking about Libre 3 plus integration, Lyumjev approval, Mobi tubeless, extended wear infusion sets and a lot more with VP of Product Management Marisa Fienup. She's also answering your questions about tubing, alerts, and shares what's next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Information on RocketAP and other closed loop research Tandem earnings call info here  Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.